Better Health for All

Enanta Pharmaceuticals' core business is the research and development of small molecule drugs for viral infections and liver diseases, including RSV, SARS-CoV-2, and hepatitis B, focusing on unmet medical needs and developing curative therapies.

This indicates that 100% of its product portfolio and R&D investment are dedicated to improving health outcomes. The company has no revenue from products with negative health impacts. Enanta conducts clinical trials, such as a Phase 2b trial for zelicapavir (EDP-938) involving approximately 180 patients, and obtains regulatory and ethics committee approvals for expanded access requests. The company also supports STEM education through partnerships with local community foundations and high schools.

Fair Money & Economic Opportunity

Enanta Pharmaceuticals is a biotechnology company focused on drug discovery and development, not a financial institution.

The provided articles contain no evidence that the company offers lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity are not applicable, as the company's core business lies outside the scope of financial services.

Honest & Fair Business

Enanta Pharmaceuticals has a Code of Business Conduct and Ethics, amended as of November 21, 2024, which includes expanded whistleblower protections.

Employees can report violations openly or anonymously via a dedicated telephone number or online portal, and a record of all complaints is provided to the Audit Committee quarterly. The policy explicitly states that nothing limits an employee's ability to file charges with government agencies or receive whistleblower awards. The company has a Compensation Clawback Policy, applicable to executive officers, allowing for the recovery of incentive compensation if financial restatements occur due to fraud or intentional misconduct. The Board of Directors has determined that six directors are independent as defined by Nasdaq standards. Enanta has an anti-bribery and anti-corruption policy that prohibits bribes and kickbacks globally, mentions the Foreign Corrupt Practices Act, and requires annual acknowledgment of the Code of Business Conduct and Ethics by employees. The effectiveness of the company’s internal control over financial reporting as of September 30, 2023, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, which also audited financial statements for the years ended September 30, 2021, 2020, and 2019.

Kind to Animals

Enanta Pharmaceuticals, Inc. conducts pre-clinical animal testing and has significant involvement in animal testing.

However, the provided articles do not offer any specific quantitative data or details regarding the percentage of cruelty-free certified products, the extent of alternative testing methods used, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy details, animal testing volume, R&D investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaborations, or public policy engagement related to animal welfare. Therefore, no KPIs can be scored.

No War, No Weapons

Enanta Pharmaceuticals, a biotechnology company, strictly prohibits the carrying or possession of any type of weapon or firearm on its premises, including for licensed individuals, with violations leading to immediate termination.

The company's Code of Business Conduct and Ethics was amended on November 21, 2024. Officers and directors are required to complete a conflict-of-interest disclosure annually, and employees acknowledge the Code upon hiring and are encouraged to review it annually. Enanta recognizes the importance of human rights for employees and subcontractors, operating under policies that prohibit child labor, forced labor, and human trafficking, and has zero-tolerance for human rights violations.

Planet-Friendly Business

Enanta Pharmaceuticals has not reported any environmental compliance violations, fines, or regulatory actions.

The company operates primarily through two leased facilities and outsources its manufacturing and commercialization for its initial product candidates. While the company maintains a comprehensive Environmental, Health, and Safety (EHS) program and reports on categories such as airborne emissions, waterborne effluents, and waste disposal, specific quantitative metrics for these areas are not provided.

Respect for Cultures & Communities

No specific, quantitative data points were found in the provided articles to assess Enanta Pharmaceuticals, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value.

The articles consistently indicate a lack of information regarding community engagement, cultural sensitivity, cultural impact assessments, local employment, grievance mechanisms, FPIC participation, community governance, cultural preservation, procurement, or charitable giving related to cultural heritage.

Safe & Smart Tech

The company's privacy policy, effective December 7, 2012, states that users can access, correct, and delete their data, which aligns with industry-standard user privacy controls.

Annual third-party network penetration testing is conducted. The company also states that it uses the NIST Framework where appropriate, and its privacy policy mentions compliance with federal and state laws regarding consumer privacy and data security, but no specific regulatory compliance details are provided.

Zero Waste & Sustainable Products

Enanta Pharmaceuticals states compliance with all relevant environmental laws and regulations, including those related to hazardous materials, and has a comprehensive Environmental, Health, and Safety (EHS) program that covers hazardous waste management.

The company has not reported any specific waste disposal violations, fines, or regulatory actions.